Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MPN Congress 2022 | An update on the safety and efficacy of rusfertide in polycythemia vera

Yelena Ginzburg • 24 Oct 2022
MPN Congress 2022
Myeloproliferative Neoplasms Polycythemia Vera Rare Diseases Rusfertide

Yelena Ginzburg, MD, Icahn School of Medicine at Mount Sinai, New York City, NY, discusses the efficacy and side effects associated with the use of rusfertide in polycythemia vera (PV), explaining that current studies have reported high efficacy rates and low rates of toxicity. This interview took place at the 14th International Congress on Myeloproliferative Neoplasms (MPN Congress) held in New York City, NY.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals